Information Provided By: 
Fly News Breaks for August 8, 2018
BCRX
Aug 8, 2018 | 06:38 EDT
JPMorgan analyst Jessica Fye reinstated coverage of BioCryst Pharmaceuticals with an Overweight rating and $9 price target following a period of restriction. The rating is unchanged from the prior coverage. The analyst believes prior APeX-1 results point to an effective hereditary angioedema attack prevention agent in BCRX7353. She sees potential for the drug to represent an attractive treatment option in the "evolving HAE landscape as a convenient once-daily oral therapy."
News For BCRX From the Last 2 Days
There are no results for your query BCRX
